DC
ALDX icon

Diametric Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Diametric Capital’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,575
Closed -$224K – 344
2023
Q1 		$224K Buy
+22,575
New +$160K 0.11% 221
2021
Q2 		– Sell
-10,375
Closed -$123K – 136
2021
Q1 		$123K Buy
+10,375
New +$119K 0.09% 136

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Diametric Capital's ALDX Position: Q2 2023 in Review

Diametric Capital sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 22,575 shares — an estimated $224K sold.

Diametric Capital first reported a position in ALDX in Q1 2021 and held it in 2 quarters. The position peaked at $224K in Q1 2023. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Diametric Capital reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Diametric Capital sold 22,575 Aldeyra Therapeutics shares in Q2 2023, an estimated $224K.
  • Diametric Capital first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 2 quarters.
  • Diametric Capital's Aldeyra Therapeutics position peaked at $224K in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Diametric Capital's 13F filing for Q2 2023, filed 11 Aug 2023.